TY - JOUR
T1 - Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible egfr tyrosine kinase inhibitors
AU - Landi, Lorenza
AU - Tiseo, Marcello
AU - Chiari, Rita
AU - Ricciardi, Serena
AU - Rossi, Elisa
AU - Galetta, Domenico
AU - Novello, Silvia
AU - Milella, Michele
AU - D'Incecco, Armida
AU - Minuti, Gabriele
AU - Tibaldi, Carmelo
AU - Salvini, Jessica
AU - Facchinetti, Francesco
AU - Haspinger, Eva Regina
AU - Cortinovis, Diego
AU - Santo, Antonio
AU - Banna, Giuseppe
AU - Catino, Annamaria
AU - Giajlevra, Matteo
AU - Crinò, Lucio
AU - De Marinis, Filippo
AU - Cappuzzo, Federico
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Background The purpose of this study was to evaluate the efficacy of afatinib in EGFR-mutant metastatic NSCLC patients with acquired resistance to erlotinib or gefitinib. Materials and Methods We retrospectively analyzed the outcome of patients with EGFR-mutant advanced NSCLC treated with afatinib after failure of chemotherapy and EGFR TKIs. Results A total of 96 individuals were included in the study. According to EGFR status, most patients (n = 63; 65.6%) harbored a deletion in exon 19, and de novo T790M mutation was detected in 2 cases (T790M and exon 19). Twenty-four (25%) patients underwent repeated biopsy immediately before starting afatinib and secondary T790M was detected in 8 (33%) samples. Among the 86 patients evaluable for efficacy, response rate was 11.6%, with a median progression free-survival (PFS) and overall survival (OS) of 3.9 and 7.3 months, respectively. No significant difference in PFS and OS was observed according to type of last therapy received before afatinib, type of EGFR mutation or adherence to Jackman criteria, and patients benefiting from afatinib therapy had longer PFS and OS (P
AB - Background The purpose of this study was to evaluate the efficacy of afatinib in EGFR-mutant metastatic NSCLC patients with acquired resistance to erlotinib or gefitinib. Materials and Methods We retrospectively analyzed the outcome of patients with EGFR-mutant advanced NSCLC treated with afatinib after failure of chemotherapy and EGFR TKIs. Results A total of 96 individuals were included in the study. According to EGFR status, most patients (n = 63; 65.6%) harbored a deletion in exon 19, and de novo T790M mutation was detected in 2 cases (T790M and exon 19). Twenty-four (25%) patients underwent repeated biopsy immediately before starting afatinib and secondary T790M was detected in 8 (33%) samples. Among the 86 patients evaluable for efficacy, response rate was 11.6%, with a median progression free-survival (PFS) and overall survival (OS) of 3.9 and 7.3 months, respectively. No significant difference in PFS and OS was observed according to type of last therapy received before afatinib, type of EGFR mutation or adherence to Jackman criteria, and patients benefiting from afatinib therapy had longer PFS and OS (P
KW - Acquired resistance
KW - Afatinib
KW - Erlotinib
KW - Gefitinib
KW - NSCLC
UR - http://www.scopus.com/inward/record.url?scp=84908131211&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908131211&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2014.07.002
DO - 10.1016/j.cllc.2014.07.002
M3 - Article
C2 - 25242668
AN - SCOPUS:84908131211
VL - 15
SP - 411-417.e4
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
SN - 1525-7304
IS - 6
ER -